MedTrace Logo

Prospective Surveillance for Very Early Hepatocellular Carcinoma

NCT03588442 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 10000

Last updated 2020-05-22

No results posted yet for this study

Summary

Hepatocellular carcinoma is one the leading cause of increasing cancer-specific mortality worldwide. Early diagnosis of hepatocellular carcinoma provides opportunity for curative therapeutic approaches and relatively favorable prognosis. Herein, we intended to establish a biosignature for early diagnosis of hepatocellular carcinoma and stratification of risk population for intensive follow-up by implementing biannual follow-up investigation and collecting peripheral blood samples for screening.

Conditions

  • Carcinoma, Hepatocellular

Sponsors & Collaborators

  • Eastern Hepatobiliary Surgery Hospital

    lead OTHER

Principal Investigators

  • Hongyang Wang, MD and PhD · Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China

  • Jinlin Hou, MD · Nanfang Hospital, Southern Medical University

Eligibility

Min Age
30 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-07-15
Primary Completion
2022-07-15
Completion
2023-07-15

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03588442 on ClinicalTrials.gov